The short answer
L-5-HTP can cause drowsiness and may add to carbinoxamine-related impairment. This is an alertness precaution; the reviewed evidence does not establish serotonin syndrome from this exact antihistamine combination.
What this answer covers
Oral carbinoxamine with the specific preparation described below.
- Supplement or preparation
- L-5-HTP
- Medication ingredient
- carbinoxamine
The supplement has its own drowsiness warning
L-5-HTP guidance cautions about drowsiness and activities requiring alertness. Carbinoxamine also has a drowsiness warning, so overlapping impairment deserves review even though no exact combination event rate was established.
A sleep trial does not measure added daytime impairment
A small study in older adults found improvements in some sleep measures with daily 5-HTP. It did not test carbinoxamine co-use or measure the additional sedation, driving risk or respiratory effects of the combination.
Keep serotonin and antihistamine effects separate
The supplement’s restrictions with antidepressants should not automatically turn this sedating H1 antihistamine into a serotonergic antidepressant. Studies of other antihistamines in mice likewise do not establish a serotonin-syndrome interaction for this exact pair.
Review the whole alertness burden
Bring the exact supplement label and all medicines to your pharmacist, particularly if carbinoxamine already makes you sleepy, dizzy or confused. Avoid driving when affected. The reviewed evidence does not identify a supplement dose or hours-apart schedule that guarantees normal alertness.
Evidence and practical considerations
Side effects & toxicity
L-5-HTP can cause drowsiness and may add to carbinoxamine-related impairment. This is an alertness precaution; the reviewed evidence does not establish serotonin syndrome from this exact antihistamine combination.
- Exact scope
- Oral carbinoxamine with the specific preparation described below. with Oral carbinoxamine; the hyoscine source, where relevant, is explicitly transdermal.
- Medication form and route
- oral
What remains uncertain
- Conditional drowsiness precaution from supplement monograph and exact H1 medicine warning. Sleep trial is not co-use safety evidence; serotonergic antidepressant restrictions and other-antihistamine mouse findings cannot be transferred to this exact drug.
Factors that may matter: Exact preparation and amount; Other medicines with overlapping effects; Route and gut-transit status where relevant.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral carbinoxamine.
Carbinoxamine is a sedating antihistamine with anticholinergic activity. The immediate-release label cautions about sedatives and tranquilizers; MAO inhibitors are separately contraindicated.
How this applies: Exact active ingredient and oral-route context.
Label warnings do not measure every exact supplement pair or provide a universal safe supplement dose or interval.
Source 2: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed extended-release carbinoxamine maleate.
Warns of marked drowsiness and additional CNS depressant effects; anticholinergic effects matter in gastrointestinal obstruction.
How this applies: Additional exact-ingredient formulation context.
Extended-release exposure is not an immediate-release schedule. No exact botanical event rate.
Source 3: Regulatory supplement monograph
webprod.hc-sc.gc.ca · Source check Sep 10, 2026
Population: People considering the covered oral L-5-HTP preparations.
Warns about drowsiness and driving; antidepressant restrictions are stated separately.
How this applies: Supports conditional alertness caution without inventing serotonin syndrome.
A sedating H1 antihistamine is not automatically a serotonergic antidepressant. No exact meclizine or carbinoxamine event rate.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Thirty older adults in a single-blind study.
Some sleep measures improved, particularly among poor sleepers.
How this applies: Limited supplement-alone human context.
Not an exact antihistamine co-use study; improved sleep does not measure added daytime impairment or respiratory depression.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft with exact preparation limits, contrary findings and source-access details. Clinical review not recorded. | |
| Research summary published |
Article revision: 32caaa54739d2a9c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.